News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Radient Pharmaceuticals and Perceptive Imagineering, LLC Announce Partnership to Accelerate Commercialization of Onko-Sure(TM) in Vitro Diagnostic Cancer Test

6/2/2010 8:15:28 AM

TUSTIN, CA--(Marketwire - 06/02/10) - Radient Pharmaceuticals Corporation, a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into a strategic partnership agreement with Perceptive Imagineering LLC to expand the commercialization of RPC's Onko-Sure™ IVD cancer test in Latin America.

Under the terms of the agreement, Perceptive Imagineering will represent RPC and conduct product registration, marketing, sales and support for the licensing and distribution of Onko-Sure as a cancer screen in Central America, South America, Mexico and the Caribbean. Beginning with Colombia, Perceptive will seek government approval and work with regional and government leaders to promote brand and product awareness for Onko-Sure as a general cancer screen. Perceptive will also develop an Onko-Sure branded website adapted for the Latin American culture.

According to Dr. Nancy Alvarez, President of Perceptive Imagineering, "It is our belief that if RPC and Perceptive can offer a non-invasive test that has the potential of detecting cancer in early stages, then the general Colombian population will be more proactive in seeking medical treatment for the deadly disease of cancer. One of the largest issues in Colombia and throughout South America in general, is a lack of urgency in seeking medical attention for health conditions. Many times people will only seek medical attention when they've had symptoms for extended periods of time. For people with cancer, this means the disease may be in stage three or four when the probability of curing the disease has been severely compromised. With the ability of potentially detecting cancer in earlier stages with Onko-Sure we hope to make proactive cancer testing a more culturally accepted practice. Our focus is to launch a full cancer screening awareness campaign in partnership with Radient Pharmaceuticals."

Radient Pharmaceuticals' Chairman and CEO Douglas MacLellan commented, "We have great confidence in Dr. Alvarez and her team's ability to successfully market and sell Onko-Sure in Latin America. Perceptive's knowledge and deep understanding of this market make them an ideally-suited partner for RPC. We continue to execute an aggressive worldwide commercialization plan for Onko-Sure and are working diligently to help governments and healthcare professionals battle the deadly disease of cancer."

Dr. Alvarez continued, "We understand the medical approval process is different in each Central and South American country and we are well-equipped to ensure the execution of a viable commercialization plan consistent with the culture and needs of each market's respective medical systems."

Perceptive specializes in assisting US medical companies in bringing their products into Latin America. Perceptive Imagineering, LLC is led by Dr. Nancy Alvarez, and, under her leadership, her company is well-suited to lead the licensing, distribution and commercialization efforts for RPC's Onko-Sure cancer test in this market.

Dr. Alvarez is a frequent guest speaker in the Colombian media and has appeared on television regularly while attending the Metropolitan University of Colombia, where she received a degree in general medicine and surgery. Dr. Alvarez has also been a featured guest with U.S. broadcast media.

Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko-Sure is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer screen and cancer monitoring tool.

RPC Contact Information: For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at For Investor Relations information, contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals: Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical's current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit

Forward Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

RPC Contact: Kristine Szarkowitz Director-Investor Relations Email Contact Tel: 206.310.5323

Read at

comments powered by Disqus